Produktinformation
- 6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane
- Chromanol 239B
- Ethanesulfonamide, N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-methyl-, trans-
- Ethanesulfonamide, N-[(3R,4S)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-, rel-
- N-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N-methylethanesulfonamide
- N-[(3R,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- N-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- Trans-N-[6-Cyano-3,4-Dihydro-3-Hydroxy-2,2-Dimethyl-2H-1-Benzopyran-4-Yl]-N-Methyl-Ethanesulfonamide
- rel-N-[(3R,4S)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methylethanesulfonamide
Chromagnol is a drug that inhibits the enzyme protein kinase C (PKC). It has been shown to have inhibitory properties on cardiac muscle cells and whole-cell recordings of heart cells. Chromagnol has also been shown to affect the function of bowel disease, including papillary muscle. Chromagnol has been shown to have effects on cardiac and atrial tissue. This drug may be a potential treatment for autoimmune diseases, such as multiple sclerosis, or other diseases that are caused by PKC overactivity. The mechanisms of action are not fully understood but it is believed that chromanol binds to the cytosolic Ca2+ ion channel, preventing it from opening and releasing Ca2+, which leads to an increase in intracellular Ca2+.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FC166930 Chromagnol
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.